(Q40905930)

24 September 2017

1 reference

title

Clinical pharmacokinetics of idarubicin (English)

1 reference

24 September 2017

1 reference

J Robert

1

1 reference

24 September 2017

1 April 1993

1 reference

Clinical Pharmacokinetics

24 September 2017

1 reference

24 September 2017

24

1 reference

24 September 2017

4

1 reference

24 September 2017

275-288

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199324040-00002

24 September 2017

0 references

cites work

Plasma pharmacokinetics of Idarubicin and its 13-hydroxymetabolite after intravenous and oral administration under fasting and non-fasting conditions

1 reference

12 December 2020

Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors

1 reference

12 December 2020

Idarubicin plus Cytarabine versus Doxorubicin plus Cytarabine in Induction Therapy for Acute Non- Lymphoid Leukaemia: A Randomized Trial

1 reference

12 December 2020

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

1 reference

12 December 2020

Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer

1 reference

12 December 2020

Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients

1 reference

12 December 2020

Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters

1 reference

12 December 2020

Hepatic extraction of adriamycin in patients with hepatocellular carcinoma

1 reference

12 December 2020

Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells.

1 reference

12 December 2020

Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.

1 reference

12 December 2020

Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study

1 reference

12 December 2020

Stereoselectivity of idarubicin reduction in various animal species and humans

1 reference

12 December 2020

Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumors

1 reference

12 December 2020

Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases

1 reference

12 December 2020

Phase I study of 4-demethoxydaunorubicin by oral route in patients with advanced cancer

1 reference

12 December 2020

Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells in vitro

1 reference

12 December 2020

Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin

1 reference

12 December 2020

Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients

1 reference

12 December 2020

Idarubicin: a second-generation anthracycline

1 reference

12 December 2020

Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-e

1 reference

12 December 2020

Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer

1 reference

12 December 2020

Intravesical instillation of doxorubicin hydrochloride and its incorporation into bladder tumors

1 reference

12 December 2020

Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors

1 reference

12 December 2020

Comparative mammalian metabolism of adriamycin and daunorubicin

1 reference

12 December 2020

Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer

1 reference

12 December 2020

Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies

1 reference

12 December 2020

Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology

1 reference

12 December 2020

Bioavailability and pharmacology of oral idarubicin

1 reference

12 December 2020

Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients

1 reference

12 December 2020

Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion

1 reference

12 December 2020

Pharmacokinetic study of intravenous and oral idarubicin in cancer patients

1 reference

12 December 2020

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

1 reference

12 December 2020

Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers

1 reference

12 December 2020

Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia

1 reference

12 December 2020

Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity

1 reference

12 December 2020

Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects

1 reference

12 December 2020

Evaluation of new anthracycline analogs with the human tumor stem cell assay

1 reference

12 December 2020

Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia

1 reference

12 December 2020

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

12 December 2020

Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia

1 reference

12 December 2020

A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer

1 reference

12 December 2020

Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity

1 reference

12 December 2020

P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins.

1 reference

12 December 2020

Clinical pharmacology of 4-demethoxydaunorubicin (DMDR)

1 reference

12 December 2020

Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses

1 reference

12 December 2020

Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients

1 reference

12 December 2020

Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

12 December 2020

Antitumor activity of 4-demethoxydaunorubicin administered orally

1 reference

12 December 2020

Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study

1 reference

12 December 2020

Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests

1 reference

12 December 2020

Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients

1 reference

12 December 2020

Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.

1 reference

12 December 2020

Clinical pharmacokinetics of doxorubicin

1 reference

12 December 2020

Aspects of cytotoxic drug penetration, with particular reference to anthracyclines

1 reference

12 December 2020

Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin

1 reference

12 December 2020

Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer

1 reference

12 December 2020

Phase I trial of 4-demethoxydaunorubicin with single i.v. doses

1 reference

12 December 2020

10.2165/00003088-199324040-00002

Identifiers

DOI

1 reference

PubMed ID

8491056

Dimensions Publication ID

24 September 2017

0 references

1 reference

PubMed ID

8491056